AP
ALXN

AHL Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

AHL Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$830K Sell
6,938
-21,965
-76% -$2.67M 0.01% 937
2017
Q3 		$4.05M Buy
28,903
+10,932
+61% +$1.49M 0.07% 449
2017
Q2 		$2.19M Buy
+17,971
New +$2.09M 0.05% 595
2016
Q1 		– Sell
-2,678
Closed -$511K – 855
2015
Q4 		$511K Buy
2,678
+889
+50% +$155K 0.04% 462
2015
Q3 		$280K Sell
1,789
-22,455
-93% -$4.1M 0.04% 584
2015
Q2 		$4.38M Buy
24,244
+1,169
+5% +$202K 0.17% 243
2015
Q1 		$4M Buy
23,075
+15,456
+203% +$2.8M 0.16% 271
2014
Q4 		$1.41M Buy
+7,619
New +$1.41M 0.07% 546

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AHL Partners's ALXN Position: Q4 2017 in Review

AHL Partners reduced its Alexion Pharmaceuticals (ALXN) stake by 76% in Q4 2017, selling an estimated $2.67M and leaving 6,938 shares worth $830K. The position accounts for 0.01% of the portfolio, ranked #937.

AHL Partners first reported a position in ALXN in Q4 2014 and has held it in 8 quarters since. The position peaked at $4.38M in Q2 2015. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

  • AHL Partners held 6,938 shares of Alexion Pharmaceuticals worth $830K as of Q4 2017.
  • AHL Partners sold 21,965 Alexion Pharmaceuticals shares in Q4 2017, an estimated $2.67M.
  • Alexion Pharmaceuticals made up 0.01% of AHL Partners's portfolio in Q4 2017, its #937 holding.
  • AHL Partners first reported a position in Alexion Pharmaceuticals in Q4 2014 and has held it in 8 quarters since.
  • AHL Partners's Alexion Pharmaceuticals position peaked at $4.38M in Q2 2015.
  • 587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.